Adagene Inc. (FRA:978)
Germany · Delayed Price · Currency is EUR 2.080
+0.020 (0.97%)
Last updated: Oct 23, 2026, 3:25 PM CEST
Adagene Employees
Adagene had 128 employees as of December 31, 2025. The number of employees decreased by 10 or 7.25% compared to the previous year.
Employees
128
Change (1Y)
-10
Growth (1Y)
-7.25%
Revenue / Employee
€63,533
Profits / Employee
€140,260
Market Cap
144.50M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 128 | -10 | -7.25% |
| Dec 31, 2024 | 138 | -36 | -20.69% |
| Dec 31, 2023 | 174 | -74 | -29.84% |
| Dec 31, 2022 | 248 | -11 | -4.25% |
| Dec 31, 2021 | 259 | 61 | 30.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fresenius SE & Co. KGaA | 178,486 |
| Bayer Aktiengesellschaft | 87,830 |
| Siemens Healthineers AG | 74,300 |
| Merck KGaA | 62,136 |
| MEDICLIN Aktiengesellschaft | 7,048 |
| Stratec SE | 1,383 |
| Medios AG | 989 |
| LIMES Schlosskliniken AG | 314 |
Adagene News
- 6 days ago - Adagene Transcript: Chardan's 10th Annual Healthcare Conference - Transcripts
- 11 days ago - Adagene Transcript: H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference - Transcripts
- 12 days ago - Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference - GlobeNewsWire
- 4 weeks ago - Adagene announces China’s NMPA approved IND for ADG138 - TheFly
- 4 weeks ago - Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager - GlobeNewsWire
- 5 weeks ago - Adagene Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 5 weeks ago - Adagene Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 6 weeks ago - Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology - GlobeNewsWire